PARP1 and cancer: Although approximately 470,000 (48%) of 977,628 newly diagnosed cancers each year in the US may have PTEN defects, only a subset of these cancers will have PTEN mutations that result in homologous recombination defects and sensitivity to PARP inhibitors [28, 39, 41–51].